WO2015084384A1 - Composés utiles en tant qu'inhibiteurs de la kinase atr - Google Patents

Composés utiles en tant qu'inhibiteurs de la kinase atr Download PDF

Info

Publication number
WO2015084384A1
WO2015084384A1 PCT/US2013/073482 US2013073482W WO2015084384A1 WO 2015084384 A1 WO2015084384 A1 WO 2015084384A1 US 2013073482 W US2013073482 W US 2013073482W WO 2015084384 A1 WO2015084384 A1 WO 2015084384A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cancer
cell
independently selected
formula
Prior art date
Application number
PCT/US2013/073482
Other languages
English (en)
Inventor
Dean Boyall
Jean-Damien Charrier
Chris Davis
Steven Durrant
Gorka ETXEBARRIA I JARDI
Damien Fraysse
David Kay
Ronald Knegtel
Joanne Pinder
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to JP2016536710A priority Critical patent/JP2016540773A/ja
Priority to EP13811718.9A priority patent/EP3077393A1/fr
Priority to PCT/US2013/073482 priority patent/WO2015084384A1/fr
Publication of WO2015084384A1 publication Critical patent/WO2015084384A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés utiles en tant qu'inhibiteurs de la protéine kinase ATR. Cette invention concerne également des compositions pharmaceutiquement acceptables comprenant lesdits composés; des méthodes permettant de traiter des maladies, troubles, et états pathologiques divers à l'aide desdits composés; des procédés de préparation des composés selon l'invention; des intermédiaires pour préparer ces composés; et des procédés d'utilisation desdits composés dans des applications in vitro, telles que l'étude des kinases dans des phénomènes biologiques et pathologiques, l'étude des voies de transduction du signal intracellulaire médiées par de telles kinases, et l'évaluation comparative de nouveaux inhibiteurs de kinases. Les composés selon l'invention sont représentés par la formule (I-A) et par la formule (I-B). Cette invention concerne également un sel pharmaceutiquement acceptable desdits composés, les variables étant telles que définies dans la description.
PCT/US2013/073482 2013-12-06 2013-12-06 Composés utiles en tant qu'inhibiteurs de la kinase atr WO2015084384A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2016536710A JP2016540773A (ja) 2013-12-06 2013-12-06 Ａｔｒキナーゼの阻害剤として有用な化合物
EP13811718.9A EP3077393A1 (fr) 2013-12-06 2013-12-06 Composés utiles en tant qu'inhibiteurs de la kinase atr
PCT/US2013/073482 WO2015084384A1 (fr) 2013-12-06 2013-12-06 Composés utiles en tant qu'inhibiteurs de la kinase atr

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/073482 WO2015084384A1 (fr) 2013-12-06 2013-12-06 Composés utiles en tant qu'inhibiteurs de la kinase atr

Publications (1)

Publication Number Publication Date
WO2015084384A1 true WO2015084384A1 (fr) 2015-06-11

Family

ID=49877037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/073482 WO2015084384A1 (fr) 2013-12-06 2013-12-06 Composés utiles en tant qu'inhibiteurs de la kinase atr

Country Status (3)

Country Link
EP (1) EP3077393A1 (fr)
JP (1) JP2016540773A (fr)
WO (1) WO2015084384A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046216A1 (fr) * 2015-09-17 2017-03-23 Astrazeneca Ab Dérivés 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinoléin-2-one utilisés en tant que modulateurs sélectifs de l'ataxie télangiectasie mutée (atm) kinase pour le traitement du cancer
WO2017059357A1 (fr) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
WO2020064971A1 (fr) 2018-09-26 2020-04-02 Merck Patent Gmbh Combinaison d'un antagoniste de pd-1, d'un inhibiteur d'atr et d'un agent de platination pour le traitement du cancer
WO2020078905A1 (fr) 2018-10-15 2020-04-23 Merck Patent Gmbh Polythérapie utilisant des agents d'alkylation d'adn et des inhibiteurs d'atr
WO2022078480A1 (fr) 2020-10-16 2022-04-21 上海迪诺医药科技有限公司 Dérivé trihétérocyclique, ainsi que composition pharmaceutique et application de celui-ci
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003065A2 (fr) * 2009-07-02 2011-01-06 Genentech, Inc. Composés pyrazolopyrimidine inhibiteurs des jak et procédés
WO2012100342A1 (fr) * 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine et dérivés de pyrazolopyrimidine en tant que modulateurs du récepteur de la mélanocortine-4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001349A (es) * 2006-08-04 2009-04-17 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003065A2 (fr) * 2009-07-02 2011-01-06 Genentech, Inc. Composés pyrazolopyrimidine inhibiteurs des jak et procédés
WO2012100342A1 (fr) * 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine et dérivés de pyrazolopyrimidine en tant que modulateurs du récepteur de la mélanocortine-4

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY", vol. 172-178, 1995, pages: 949 - 982
"The Merck Manual", 1999
CHIANG ET AL.: "Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family", METHODS MOL. BIOL., vol. 281, 2004, pages 125 - 41
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO.
GREENE, T.W.; WUTS, P. G: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
HALL-JACKSON ET AL., ONCOGENE, vol. 18, 1999, pages 6707 - 6713
HICKSON ET AL.: "Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM", CANCER RESEARCH, vol. 64, 2004, pages 9152 - 9159
KIM ET AL., ONCOGENE, vol. 21, 2002, pages 3864
KIM ET AL.: "Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members", THE JOURNAL OFBIOLOGICAL CHEMISTRY, vol. 274, no. 53, 1999, pages 37538 - 37543
KUMAGAI ET AL., CELL, vol. 124, 10 March 2006 (2006-03-10), pages 943 - 955
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SARKARIA ET AL.: "Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine", CANCER RESEARCH, vol. 59, 1999, pages 4375 - 5382
SONA HUBACKOVA ET AL: "Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling", CELL CYCLE, vol. 9, no. 15, 1 August 2010 (2010-08-01), pages 3085 - 3099, XP055098453, ISSN: 1538-4101, DOI: 10.4161/cc.9.15.12521 *
TAKEMURA ET AL., JBC, vol. 281, 2006, pages 30814
UNSAL-KACMAZ ET AL., MOLECULAR AND CELLULAR BIOLOGY, February 2004 (2004-02-01), pages PL292 - 1300
UNSAL-KACMAZ ET AL., PNAS 99, vol. 10, 14 May 2002 (2002-05-14), pages 6673 - 6678

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033284B1 (ru) * 2015-09-17 2019-09-30 Астразенека Аб ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
US9856255B2 (en) 2015-09-17 2018-01-02 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
KR102028848B1 (ko) 2015-09-17 2019-10-04 아스트라제네카 아베 암의 치료를 위한 변이 혈관확장성 운동실조증(atm) 키나아제의 선택적 조절제로서의 8-[6-[3-(아미노)프로폭시]-3-피리딜]-1-이소프로필-이미다조[4,5-c]퀴놀린-2-온 유도체
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN108137576A (zh) * 2015-09-17 2018-06-08 阿斯利康(瑞典)有限公司 用于治疗癌症的、为共济失调毛细血管扩张症突变型（atm）激酶的选择性调节剂的8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-异丙基-咪唑并[4,5-c]喹啉-2-酮衍生物
JP2018531226A (ja) * 2015-09-17 2018-10-25 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 癌の治療のための血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターとしての８−［６−［３−（アミノ）プロポキシ］−３−ピリジル］−１−イソプロピル−イミダゾ［４，５−ｃ］キノリン−２−オン誘導体
WO2017046216A1 (fr) * 2015-09-17 2017-03-23 Astrazeneca Ab Dérivés 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinoléin-2-one utilisés en tant que modulateurs sélectifs de l'ataxie télangiectasie mutée (atm) kinase pour le traitement du cancer
AU2016323399B2 (en) * 2015-09-17 2019-04-18 Astrazeneca Ab 8-(6-(3-(amino)propoxy)-3-pyridyl)-1 -isopropyl-imidazo(4,5-c)quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer
US11613539B2 (en) 2015-09-17 2023-03-28 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10882858B2 (en) 2015-09-17 2021-01-05 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
KR20180052724A (ko) * 2015-09-17 2018-05-18 아스트라제네카 아베 암의 치료를 위한 변이 혈관확장성 운동실조증(atm) 키나아제의 선택적 조절제로서의 8-[6-[3-(아미노)프로폭시]-3-피리딜]-1-이소프로필-이미다조[4,5-c]퀴놀린-2-온 유도체
CN108137576B (zh) * 2015-09-17 2020-09-22 阿斯利康(瑞典)有限公司 8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-异丙基-咪唑并[4，5-c]喹啉-2-酮衍生物
WO2017059357A1 (fr) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
WO2020064971A1 (fr) 2018-09-26 2020-04-02 Merck Patent Gmbh Combinaison d'un antagoniste de pd-1, d'un inhibiteur d'atr et d'un agent de platination pour le traitement du cancer
WO2020078905A1 (fr) 2018-10-15 2020-04-23 Merck Patent Gmbh Polythérapie utilisant des agents d'alkylation d'adn et des inhibiteurs d'atr
WO2022078480A1 (fr) 2020-10-16 2022-04-21 上海迪诺医药科技有限公司 Dérivé trihétérocyclique, ainsi que composition pharmaceutique et application de celui-ci
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途

Also Published As

Publication number Publication date
EP3077393A1 (fr) 2016-10-12
JP2016540773A (ja) 2016-12-28

Similar Documents

Publication Publication Date Title
US9663519B2 (en) Compounds useful as inhibitors of ATR kinase
US8957078B2 (en) Compounds useful as inhibitors of ATR kinase
US8969360B2 (en) Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) Compounds useful as inhibitors of ATR kinase
AU2015277212B2 (en) Method for treating cancer using a combination of Chk1 and ATR inhibitors
US8912198B2 (en) Compounds useful as inhibitors of ATR kinase
US20130018035A1 (en) Compounds useful as inhibitors of atr kinase
EP2723746A1 (fr) Composés inhibiteurs de la kinase atr
EP2723747A1 (fr) Composés utiles comme inhibiteurs de la kinase atr
WO2013049719A1 (fr) Composés utiles en tant qu'inhibiteurs de kinase atr
WO2013071088A1 (fr) Composés utiles comme inhibiteurs de kinase atr
EP2776429A1 (fr) Composés utiles comme inhibiteurs de kinase atr
WO2013049720A1 (fr) Composés utiles en tant qu'inhibiteurs de kinase atr
EP2776419A1 (fr) Composés de pyrazine utiles comme inhibiteurs de kinase atr
US20160326180A1 (en) Compounds useful as inhibitors of atr kinase
WO2015084384A1 (fr) Composés utiles en tant qu'inhibiteurs de la kinase atr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13811718

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016536710

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013811718

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013811718

Country of ref document: EP